Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements. For the current quarter, Canopy Growth is expected ...

It has experienced a hiccup, but the company is still on the right path. That’s the opinion of Roth MKM analyst Bill Kirk on ...

Canopy Growth's revenue and EBITDA have been disappointing, and analysts' projections for FY25 and FY26 remain weak. Read why ...

Let's dive into two cannabis giants, and which one may be the better pick for long-term investors. The post Should You Buy ...

In a report released on November 8, Lisa Lewandowski from Bank of America Securities reiterated a Sell rating on Canopy Growth (CGC – Research Report), with a price target of C$ ... dampen investor ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The company saw a huge decline in Canadian adult-use cannabis, with revenues down 24% at C$18.4 million from that category, offsetting the 16% gain from Canadian medical cannabis which reached C$18.7 ...

Canopy Growth Corporation (TSX: WEED) (NASDAQ: CGC) will report the second quarter of fiscal year 2025 ended Sept. 30, before ...

The price currently set on this stock reflects its superior financial health and position in the market. In addition, it may be less risky than Canopy Growth but remains susceptible to regulatory ...

Whether it’s Canopy Growth (TSX:WEED ... Steady losses and high debt burdens have hurt this stock to a greater degree than many of its peers, and a period of deleveraging has led to share price ...